It is their projection and opinion that MDMA shall receive FDA approval for treatment of PTSD in 2023.
MDMA is capable of inducing unique psychopharmacological effects, such as:
MAPS is currently sponsoring MAPP2, the second of two Phase 3 trials to support FDA approval of this Breakthrough-designated therapy.
In (MAPS) first Phase 3 study, 88% of participants with severe PTSD experienced a clinically significant reduction in PTSD diagnostic scores two months after their third session of MDMA-assisted therapy, compared to 60% of placebo participants.
Additionally, 67% of participants in the MDMA group compared to 32% of participants in the placebo group no longer met the criteria for PTSD remission two months after the sessions.